Inspire Pharmaceuticals Inc. (ISPH, Financial) filed Quarterly Report for the period ended 2010-06-30.
Inspire Pharmaceuticals Inc. has a market cap of $423.8 million; its shares were traded at around $5.13 with and P/S ratio of 4.6. ISPH is in the portfolios of Steven Cohen of SAC Capital Advisors.
Total revenues were approximately $27.3 million for the three months ended June 30, 2010, as compared to approximately $23.1 million for the same period in 2009. The increase in 2010 revenue of approximately $4.2 million, or 18%, as compared to the same period in 2009, was due to an increase in product revenue from net sales of AzaSite and an increase in royalty revenue from net sales of Restasis.
Product sales of AzaSite, net of rebates and discounts, for the three months ended June 30, 2010 were approximately $9.6 million, as compared to approximately $7.6 million for the same period in 2009. The increase in revenue for AzaSite of approximately $2.0 million, or 27%, for the three months ended June 30, 2010, as compared to the same period in 2009, was primarily due to increased patient usage of AzaSite and an increase in prescribers of AzaSite, as evidenced by an increase of prescriptions year-over-year, as well as price increases for the product between the periods.
Total co-promotion and royalty revenue for the three months ended June 30, 2010 was approximately $17.7 million, as compared to approximately $15.5 million for the same period in 2009, representing an increase of approximately $2.2 million, or 14%.
prescriptions year-over-year, as well as a price increase effective in January 2010. For the three months ended June 30, 2010 and 2009, Allergan recorded revenue from net sales of Restasis of approximately $153 million and $121 million, respectively.
Co-promotion revenue from net sales of Elestat for the three months ended June 30, 2010 was approximately $6.5 million, as compared to approximately $6.6 million for the same period in 2009. As of January 1, 2010, all co-promotion revenue on Elestat is reco
Read the The complete Report
Inspire Pharmaceuticals Inc. has a market cap of $423.8 million; its shares were traded at around $5.13 with and P/S ratio of 4.6. ISPH is in the portfolios of Steven Cohen of SAC Capital Advisors.
Highlight of Business Operations:
Estimated subsequent costs necessary to submit an NDA for denufosol for the treatment of cystic fibrosis are projected to be in the range of $12 million to $18 million. This estimate includes completing TIGER-2 as well as conducting any additionally required toxicology studies and other ancillary studies, manufacturing denufosol for clinical trials, producing qualification lots consistent with current Good Manufacturing Practices, or cGMP, standards, salaries for development personnel, other unallocated development costs and regulatory preparation and filing costs. These costs do not include the costs of pre-launch inventory and any product approval milestones payable to Cystic Fibrosis Foundation Therapeutics, Inc. These costs are difficult to project and actual costs could be materially different from our estimate. For example, clinical trials and any other required studies may not proceed as planned, results from ongoing or future clinical trials may change our planned development program, additional Phase 3 clinical trials may be necessary and an anticipated NDA filing could be delayed.Total revenues were approximately $27.3 million for the three months ended June 30, 2010, as compared to approximately $23.1 million for the same period in 2009. The increase in 2010 revenue of approximately $4.2 million, or 18%, as compared to the same period in 2009, was due to an increase in product revenue from net sales of AzaSite and an increase in royalty revenue from net sales of Restasis.
Product sales of AzaSite, net of rebates and discounts, for the three months ended June 30, 2010 were approximately $9.6 million, as compared to approximately $7.6 million for the same period in 2009. The increase in revenue for AzaSite of approximately $2.0 million, or 27%, for the three months ended June 30, 2010, as compared to the same period in 2009, was primarily due to increased patient usage of AzaSite and an increase in prescribers of AzaSite, as evidenced by an increase of prescriptions year-over-year, as well as price increases for the product between the periods.
Total co-promotion and royalty revenue for the three months ended June 30, 2010 was approximately $17.7 million, as compared to approximately $15.5 million for the same period in 2009, representing an increase of approximately $2.2 million, or 14%.
prescriptions year-over-year, as well as a price increase effective in January 2010. For the three months ended June 30, 2010 and 2009, Allergan recorded revenue from net sales of Restasis of approximately $153 million and $121 million, respectively.
Co-promotion revenue from net sales of Elestat for the three months ended June 30, 2010 was approximately $6.5 million, as compared to approximately $6.6 million for the same period in 2009. As of January 1, 2010, all co-promotion revenue on Elestat is reco
Read the The complete Report
